Longitudinal MRI Examinations of Patients With Brain Ischemia and Blood Brain Barrier Permeability "LOBI-BBB"

Recruiting

Phase N/A Results N/A

Trial Description

The objective of this trial is to visualize blood brain barrier function and metabolic changes in the first days after ischemic stroke with new investigational MRI sequences.

Detailed Description

In this study the investigators will be examining acute ischemic stroke patients on the first and second day after symptom onset using repetitive MRI examinations to visualize blood brain barrier function and metabolic changes of the brain in 5 sub-projects, each containing a specific MRI protocol with one of the following new MRI sequences:
1. T1-Dynamics (measuring disruptions of the blood-brain barrier)
2. pH-imaging (measuring metabolic changes, acidosis)
3. Resting-state MRI (measuring changes in the cerebral perfusion)
4. Quantitative MRI-Angiography (quantification of blood flow in single vessels)
5. Diffusion Tensor Imaging (DTI) for patients with Anterior Choroidal Artery (AChA)-Infarcts (quantification of damage of white matter tracts)
Each sub-projects will be conducted in blocks of a specific time span. Morphological outcome will be assessed at day 5-7. Clinical outcome will be assessed at day 5-7 and day 90. The association of the new imaging parameter with the clinical and morphological outcome measures will be analysed. No specific intervention is assigned to the subjects by the investigators of the study.

Conditions

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample

Trial Population

Primary care clinic. Patients presenting with acute (<24h) transient ischemic attack or stroke at the emergency ward, Charité Campus Benjamin Franklin

Outcomes

Type Measure Time Frame Safety Issue
Primary clinical outcome measured with the National Institutes of Health Stroke Scale (NIHSS) on follow-up examination day 5-7 No
Primary clinical outcome measured with the modified Rankin Scale (mRS) on day 90 No
Secondary final lesion volume (measured on FLAIR images) on follow-up examination day 5-7 No

Biospecimen Retention:Samples With DNA - 2x 2ml plasma and 2x 2ml serum per patient

Sponsors